Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Green tea petition

This article was originally published in The Tan Sheet

Executive Summary

A qualified health claim petition submitted on behalf of the beverage company Ito En requests FDA approval of the statement: "Daily consumption of at least 5 fluid ounces of green tea may reduce a number of risk factors associated with cardiovascular disease." The petition, filed by AAC Consulting Group, also applies to dietary supplements containing the ingredient. The agency says it is collecting comments on the petition through Sept. 26 and will notify the firm of its final decision no later than March 10, 2006. FDA recently allowed qualified statements linking green tea to cancer prevention (1"The Tan Sheet" July 11, 2005, p. 12). Infant formula claim: A petition filed by Nestlé USA June 17 requests a qualified health claim supporting "the ability of 100% Whey Protein Partially Hydrolyzed, when used in infant formula, to reduce the risk associated with standard intact cow's milk formulas"...

You may also be interested in...



Qualified Health Claim Linking Green Tea To CVD Reduction Denied By FDA

"No credible evidence" exists to approve a qualified health claim linking green tea or green tea extract to a reduction of risk factors associated with cardiovascular disease, FDA states in a letter of denial to green tea marketer Ito En May 9

Green Tea Cancer Prevention Claims Offered By FDA Stress Data Limits

FDA emphasizes the negative in its specified wording for qualified health claims that may link green tea with prevention of breast and prostate cancers

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel